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ABSTRACT
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel 
coronavirus which has been identified as the cause of the recently emerging 
coronavirus disease 2019 (COVID-19), a respiratory-related infectious disease, 
in late 2019. As of May 2020, SARS-CoV-2 has infected millions of people 
with almost 300.000 deaths worldwide only within few months since its first 
case was reported. While this infection mostly results in mild diseases, the 
increasing number of severe cases and deaths cannot be overlooked. Due to 
its novelty, many facets of SARS-CoV-2 pathogenesis are not well understood. 
This review presents updated knowledge on the key virus characteristics of 
SARS-CoV-2 and critical notes in the pathogenesis of this viral infection in 
human that is currently proposed to largely involve various aspects of the 
host immune responses. While the immediate impact of viral infection in the 
target cells contributes to the development of the disease, the ability of the 
virus to modify the host responses may result in the dysregulation of innate 
and adaptive immune responses, which commonly manifest in the severe 
spectrum of the disease. Having deep understanding on this complex process is 
central for tailoring appropriate management for the infected patients as well 
as for developing effective preventive measures, most importantly vaccine, 
which is hoped to occur in the near future.  
ABSTRAK
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) adalah suatu 
jenis virus corona baru penyebab coronavirus disease 2019 (COVID-19), suatu 
penyakit infeksi pada saluran napas, yang muncul akhir tahun 2019. Hingga 
bulan Mei 2020, SARS-CoV-2 telah menginfeksi jutaan orang dan menyebabkan 
hampir 300.000 kematian di seluruh dunia, hanya dalam waktu beberapa 
bulan setelah kasus pertama dilaporkan. Walaupun infeksi ini sebagian 
besar menyebabkan gejala ringan, peningkatan jumlah kasus berat dan 
kematian tidak dapat diabaikan. Dikarenakan kebaruan virus ini, banyak 
aspek patogenesis SARS-CoV-2 yang belum diketahui dengan baik. Tinjauan 
ini membahas pengetahuan terkini tentang karakteristik penting virus SARS-
CoV-2 serta aspek penting patogenesis infeksi virus ini pada manusia, yang 
melibatkan berbagai komponen respon imun inang. Walaupun efek langsung 
infeksi virus pada sel target berperan dalam perkembangan penyakit, 
kemampuan virus ini untuk memodifikasi respon inang dapat menyebabkan 
disregulasi respon imun bawaan dan adaptif, yang bermanifestasi menjadi 
penyakit yang berat. Pemahaman mendalam kompleksitas proses ini sangat 
diperlukan dalam penentuan manajemen yang tepat untuk pasien yang 
terinfeksi dan dalam upaya prevensi yang efektif, seperti vaksin, yang 
diharapkan dapat diwujudkan dalam waktu dekat.
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INTRODUCTION
At the end of 2019, an outbreak 
of a new coronavirus (CoV) infection 
causing respiratory-related illness 
was reported in Wuhan, China. On 
11 February 2020, the World Health 
Organization (WHO) officially named 
the disease as coronavirus disease 2019 
(COVID-19).1,2 COVID-19 is not the first 
severe respiratory disease outbreaks 
caused by the coronaviruses. In the 
past two decades, coronaviruses have 
caused three epidemic diseases, namely, 
COVID-19, severe acute respiratory 
syndrome (SARS) and Middle East 
respiratory syndrome (MERS).3,4 The 
new CoV as the causative agent of this 
respiratory disease was identified and 
its genome was fully sequenced. Based 
on the phylogeny and taxonomy and 
due to a close relationship to SARS-CoV 
which caused SARS, the International 
Committee on Taxonomy of Viruses 
(ICTV) named this novel CoV as SARS-
CoV-2.5
Since its first reported case in late 
2019, this viral infection has spread 
to almost all parts of the world, with 
variable transmission rates, mortality 
rates, and clinical manifestations were 
reported between countries. It may take 
years until we can fully comprehend the 
whole picture of the characteristics of 
the pathogen and its likely origin, clinical 
manifestations, and the host immune 
responses in controlling the infection. In 
this review, we provide understanding 
on how this novel disease develops in 
human and to serve as scientific basis 
on selecting and/or developing the best 
management, both preventive and 
curative, as an initial effort to control the 
infection globally. The characteristics 
of the virus and possible (immuno)-
pathogenesis of the disease will be 





SARS-CoV-2 belongs to the 
Coronavirinae subfamily in the 
Coronaviridae family. CoVs are large 
enveloped virus which contain a 
positive-sense single-stranded RNA 
as their genome. Based on their 
genomic structures,  CoV  subfamily 
can   be    classified   into   4  genera: 
Alphacoronavirus, Betacoronavirus, 
Gammacoronavirus, and 
Deltacoronavirus. Naturally,        they are 
zoonotic, with alphacoronaviruses and 
betacoronaviruses have mammals as 
their hosts, while gammacoronaviruses 
and deltacoronaviruses mostly infect 
birds.6
There are currently seven CoVs 
that are known to be transmitted 
from animals to humans, including 
the newly emerged SARS-CoV-2.1,7 Two 
(HCoV-NL63 and HCoV-229E) are of the 
Alphacoronavirus and five (HCoV-OC43, 
HCoV-HKU1, SARS-CoV, MERS-CoV, and 
SARS-CoV-2) are of the Betacoronavirus 
genus.  With the exception of SARS-CoV, 
MERS-CoV, and SARS-CoV-2, most of these 
human CoVs usually cause mild common 
cold-like illness in immunocompetent 
individuals. In contrast, viral pneumonia 
and severe respiratory distress have 
been shown to occur in response to the 
previously pandemics SARS-CoV (in 2002-
2003) and MERS-CoV (in 2012), resulting 
in mortality rates of 10% and 37%, 
respectively.7 Severe pneumonia has 
also been reported with SARS-CoV-2, and 
while mortality rate has not been able to 
be accurately measured, infection from 
this virus has resulted in 6.95% death 
globally as of the time of this writing.8
The three highly pathogenic viruses 
were suggested to emerge from bats as 
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their natural reservoirs. Recent study 
has shown that SARS-CoV-2 spike protein 
gene sequence is 93.1% identical to those 
of bat CoV RaTG13.9 However, these 
three viruses were likely to undergo 
recombination which allow them to then 
infect human cells. In the case of SARS-
CoV and MERS, civet and camel were 
thought to be the intermediary animals, 
while for SARS-CoV-2, pangolin may be 
the culprit as shown by the sequence 
similarity between pangolin CoVs and 
SARS-CoV-2.10
Viral structure & entry into the host cells
Genome-wide analysis indicated that 
SARS-CoV-2 genome sequence is 79.5% 
and 50% identical to those of SARS-CoV 
and MERS-CoV, resulting in various 
similarities between SARS-CoV-2 to the 
two latter viruses, particularly to SARS-
CoV, in terms of viral characteristics 
and pathogenesis in human.10 SARS-
CoV-2 virus particle is around 60 - 
100 nm in diameter with a round or 
slightly oval shape.11 Similar to other 
betacoronaviruses, the structure of the 
virion consists of a single-stranded RNA 
genome associated with a nucleocapsid 
which is surrounded by a phospholipid 
bilayer envelope bearing multiple 
glycoprotein projections. 
The genome is ~29.9 kb, and consists 
of at least ten open reading frames 
(ORFs) of which 6 are conserved across 
betacoronaviruses (ORF1a, ORF1b, S, 
E, M, N).11,12 The first two third of the 
RNA from the 5’-end comprises the 
overlapping ORF1a and ORF1b which 
are translated into two polypeptides and 
further processed into 15 non-structural 
proteins (nsp1-nsp16). These nsps 
form the viral replicase complex which 
function mainly in viral replication and/
or transcription. A third of the genome 
toward the 3’-terminus possesses 
multiple ORFs encoding 4 major 
structural proteins: spike (S), envelope 
(N), membrane (M), and nucleocapid (N); 
as well as accessory proteins (FIGURE 
1).13,14 S, E, and M proteins make up the 
viral envelope with M glycoprotein 
being the most abundant one. The M 
and E proteins are located among the 
spikes or S proteins and participate in 
the assembly of virus particles.11 On 
the other hand, S glycoproteins which 
protrude on the outer surface of the 
virus are particularly important in 
promoting viral infection as it mediates 
the attachment of virion to the host cell 
receptor. The S protein consists of two 
functional subunits, with the S1 subunit 
being important in the recognition and 
binding to the cell receptor and the S2 
subunit being involved in the virus-host 
membrane fusion, eventually allowing 
the delivery of viral genetic materials 
into the host cells.10
FIGURE 1. SARS-CoV-2 viral structure
273
J Med Sci, Volume 52, Number 3, 2020, July: 270-281
FIGURE 2. SARS-CoV-2 mechanism of cell entry [modified from7]
Human angiotensin-converting 
enzyme 2 (ACE2) functions mainly to 
cleave angiotensin (Ang) I to produce 
Ang-(1-7) and participates in the 
regulation of blood pressure.17 It is a 
type I transmembrane glycoprotein that 
is expressed in almost all cells in various 
organs such as lung, heart, kidney, and 
intestine.10 In the respiratory tract, the 
expression of ACE2 is widely distributed 
on the epithelial cells of trachea, 
bronchi, and alveoli, as well as on the 
alveolar macrophages and monocytes.18 
However, it has been reported that ACE2 
is particularly enriched in the surfactant-
producing alveolar type II cells (AECII) 
in the lung, as well as ciliated and goblet 
cells in the airway, making these cells 
highly vulnerable to this viral infection 
and likely serve as the portal of entry in 
human.19,20. ACE2 is also highly expressed 
on the intestinal epithelial cells and has 
diffuse expression on the endothelial 
cells of arteries and veins, epithelial cells 
of the kidney, cerebral neurons, and 
immune cells.18
Transmission
The wide distribution of this viral 
receptor provides insights on the 
transmission routes, pathogenesis, and 
clinical manifestations of SARS-CoV-2 
infection. The main source of human 
transmission is those that are infected, 
Similar to SARS-CoV, a recent 
study has confirmed that SARS-CoV-2 
uses ACE2 (angiotensin-converting 
enzyme 2) as the key receptor to enter 
the host cells, most likely via similar 
entry mechanism (FIGURE 2).15 It has 
been suggested that mutations in the 
receptor binding domain (RBD) of the 
S1 subunit account for cross-species 
recognition of SARS-CoV-2 and evolution 
in this domain possibly contributes to 
10-20 fold higher affinity of this virus to 
human ACE2 compared to SARS-CoV.10,15 
The entry process also depends on the 
presence of type II transmembrane 
serine protease TMPRSS2, which cleaves 
the ACE2 receptor and activates the viral 
S protein upon binding, resulting in the 
entry of the virus. It has been indicated 
that SARS-CoV-2 requires both ACE2 
and TMPRSS2 to enter cells, hence cells 
that possess both proteins have been 
suggested to be most susceptible to SARS-
CoV-2 infection.7,16
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and while severe patients are more 
contagious, asymptomatic infected 
patients were shown to also shed the 
virus.10 SARS-CoV-2 has been suggested 
to be mainly transmitted through 
respiratory droplet, close contact, and 
aerosols.21 One study has reported that 
SARS-CoV-2 persisted on plastic and 
stainless-steel surfaces for up to 72 
hours and remained viable in the air for 
up to 3 hours.22 Since high expression 
of ACE2 was also found in the intestine, 
faecal-oral transmission is also predicted 
with the intestine as the entry point.21 
Nevertheless, current studies highlighted 
respiratory tract as the main entry 
point, with primary viral replication 
occurring in the mucosal epithelium of 
upper respiratory tract and subsequent 
multiplication in the lower respiratory 
tract and intestinal mucosa.10
Immunopathogenesis
Several outcomes have been 
observed following SARS-CoV-2 infection: 
asymptomatic (1.2%), mild to moderate 
cases (80.9%), severe cases (13.8%), 
critical cases (4.7%), and death (2.3%). 
This  infection has been considered a 
self-limiting disease, and most people 
were recovered in 1-2 weeks. However, 
small proportion of patients, especially 
those who were elderly or had co-morbid 
conditions, experienced severe clinical 
manifestations and death due to acute 
respiratory distress syndrome (ARDS) 
and multi organs failure.10 SARS-CoV-2 
infection results in exaggerated and 
persistent lung inflammation. Since this 
virus uses the same cell receptor as SARS-
CoV, several mechanisms that are similar 
to SARS-CoV are thought to underlie the 
pathogenesis of this infection. 
Innate immune responses against SARS-
CoV-2
After successfully entering the target 
cells such as pneumocytes or endothelial 
cells, SARS-CoV-2 can initiate antiviral 
response either inside these infected 
target cells or in the uninfected tissue 
macrophages and dendritic cells that 
have taken up the lysed cells as a result of 
the infection. As with other RNA viruses, 
it is likely that SARS-CoV-2 uses viral 
RNA genome or its intermediates such 
as dsRNA as their pathogen-associated 
molecular patterns (PAMPs), which are 
recognized by the pattern recognition 
receptors (PRRs) on the host cells, in 
this case are either the endosomal RNA 
receptor, Toll-Like Receptor (TLR) 3 and 
TLR7, or the RNA sensor in the cytosol, 
Retinoic-acid Inducible Gene (RIG)-I/
melanoma differentiation-associated 
protein (MDA)5. Additionally, various 
PRRs may also recognise endogenous 
damage-associated molecular patterns 
(DAMPs) originate from the host cells, 
such as nuclear and cytosolic proteins, 
that are released by injured tissues and 
dying cells as a result of the infection.23 
These recognitions lead to the activation 
of downstream signalling and eventually 
the expression of type I interferon (IFN) 
and other pro-inflammatory cytokines. 
The binding of type I IFN to its receptor 
on host cells result in the transcription 
of IFN-stimulated genes (ISG) which can 
suppress viral replication early in the 
infection. Indeed, main effector in innate 
immune response against various virus 
infections involves type I interferon 
response pathway which is vital not 
only for controlling viral replication 
but also for inducing adaptive immune 
response.24
In the severe cases of SARS-CoV and 
MERS-CoV, high influx of macrophages 
and neutrophils are regularly observed 
(FIGURE 3).24 Tissue macrophages have 
been linked to epithelial damage that 
initiates ARDS. Macrophage activation 
leads to the production of type I and type 
III interferons, which stimulates antiviral 
states in the surrounding cells and limits 
early viral replication, as well as IL-6 
and IL-1β that are important for the 
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initiation of inflammation by recruiting 
neutrophils and cytotoxic T cells. 
Activated neutrophils release reactive 
oxygen species and leukotrienes, and 
while they are important for neutrophil-
mediated early virus control, they can 
Using a mouse model of SARS-CoV 
infection, it has been demonstrated that 
severe pneumonia was mainly caused 
by dysregulation of type 1 IFN response 
as well as inflammatory monocyte-
macrophages.24 Indeed, evidences have 
strongly suggested that alteration in 
the innate immune response correlates 
with clinical manifestations in COVID-19 
infection. As with SARS-CoV and MERS-
CoV, it is predicted that SARS-CoV-2 
utilizes various mechanisms to dampen 
type I IFN response either by suppressing 
the production of type I IFN and/or the 
signalling downstream of its receptor in 
the target cells (FIGURE 4). 
Similar to the two earlier 
pandemics, in SARS-CoV-2 infection, 
there might be a delay in type 1 IFN 
response which impairs early virus 
control, resulting in the influx of large 
number of neutrophils and monocyte-
macrophages.20,24,25 Recent studies 
have also demonstrated that COVID-19 
patients have an expanded population 
of circulating monocytes producing IL-6 
and IL-1β.25 The overproduction of pro-
inflammatory cytokines by these cells, 
particularly IL-6, IL-1β, and TNFα, and 
chemokines leads to “cytokine storm”, 
which increases the risk of widespread 
vascular hyperpermeability, systemic 
inflammation, multiorgan failure, and 
eventually death if it is uncontrolled over 
time.26 Via similar mechanism, SARS-
CoV-2 targeting other ACE2-expressing 
also directly damage pneumocytes and 
endothelial cells in the lung and cause 
acute lung injury. In fact, persistent 
neutrophil-mediated damage to the 
alveolar cells is commonly observed in 
severe or chronic viral infection.25
FIGURE 3. Contribution of innate immune responses to antiviral 
immunity and lung injury [modified from 25]
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cells in various organs contributes to 
systemic sepsis which increases the 
risk of multiple organ damages and 
fatalities.10
SARS-CoV-2 may also cause 
pyroptosis of macrophages and 
lymphocytes, contributing to peripheral 
blood lymphopenia in vast majority 
of patients.27 Studies have shown 
that patients in severe condition 
are characterized by increased total 
neutrophil, decreased lymphocytes, 
increased serum IL-6, and increased 
level of innate cytokines including IL-1β. 
Indeed, neutrophilia, lymphopenia, and 
increased level of IL-6 have been shown 
to significantly correlate with severity of 
the disease.24,25
In addition  to  mechanisms 
mentioned above, SARS-CoV-2 
infection in the lung is predicted to 
cause downregulation and promotion 
of ACE2 shedding, causing loss of 
pulmonary ACE2 function and renin-
angiotensin-system dysfunction, which 
further increase vascular permeability, 
recruitment of neutrophils, and 
exacerbate inflammatory responses.10
FIGURE 4. Proposed host immune responses and immunopathology 
during SARS-CoV-2 infection
Adaptive immune responses against 
SARS-CoV-2
The recognition of PAMPs and 
activation of innate immune responses 
lead to the induction of adaptive 
responses. T cells are particularly 
important in antiviral immunity, with 
CD4+ Th1 cells being central in shaping 
the overall adaptive immune response 
and CD8+ T cells being important in 
killing virally infected cells. On the other 
hand, neutralizing antibodies as part of 
the humoral response are important for 
limiting virus infection at later stages 
and prevent reinfection. A recent study 
has indicated that both cellular and 
humoral immunity might be required 
for effective viral clearance following 
SARS-CoV-2 infection.28
Studies examining the humoral 
response to SARS-CoV-2 infection are 
limited. From currently available 
evidences, there seems to be a slight 
difference in terms of the kinetics of 
antibody generation in SARS-CoV-2 
infection compared to the previous two 
pandemics. In SARS-CoV infection, IgM 
seroconversion is observed as early as day 
4 after onset of the disease, while MERS-
CoV infection results in a seroconversion 
on week 2-3 after onset. Following SARS-
CoV-2 infection, one study reported 
a peak of anti-nucleocapsid (N) IgM 
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level on day 9 after disease onset and 
a switch to IgG by week 2.1 Both anti-
nucleocapsid (N)-specific and anti-spike 
(S)-specific IgM and IgG, mainly in IgG1 
isotype, could be detected in recovered 
patients in a recent study, with S-specific 
IgG showing a neutralization activity.28 
Indeed, recently published study has 
observed strong correlation between 
levels of RBD-binding antibodies and 
SARS-CoV-2 neutralizing antibodies in 
PCR-confirmed COVID-19 patients.29 The 
occurrence of antibody-producing cells 
and T follicular helper cells, which are 
important for antibody production, was 
reported to coincide with the start of 
viral clearance. These findings suggested 
that neutralizing antibodies correspond 
to the protective humoral immunity 
against SARS-CoV-2 infection.28,30 Cross-
reactivity with SARS-CoV was also seen 
in sera from 5 COVID-19-confirmed 
patients, although further studies using 
larger cohorts are required.1
It has been reported that early 
development of anti-spike (S) IgG, while 
providing some control to the infection, 
correlates with more severe conditions 
via a mechanism called antibody-
dependent enhancement (ADE). This 
sub-optimal antibody response may 
create a complex with the virus which 
increases the cellular uptake and 
infection of the target cell, resulting 
in persistent viral replications.31 This 
antibody-virus complex might also 
alter inflammatory responses and 
causes severe lung injury, by promoting 
macrophages accumulation, activating 
complement classical pathway, and 
potentially mediating antibody-
dependent cell-mediated cytotoxicity 
(ADCC) mechanism.20,27
Evidences have indicated the 
requirement of T cells in controlling 
SARS-CoV-2 infection particularly at 
the later stage. In non-severe recovered 
patients, an increase in peripheral 
blood CD4+ and CD8+ T cell frequency 
was observed at around day 7-8 after 
disease onset, preceding the resolution 
of symptoms. The co-expression of CD38 
and human leukocyte antigen (HLA)-DR 
in subsets of these cells suggests activated 
cells. A recent study has demonstrated 
that following mild SARS-CoV-2 infection, 
activated CD8+ CD38+HLA-DR+ T cells 
produced greater response than that 
of their CD4+ T cells counterparts.30 In 
contrast, consistent with lymphopenia 
previously reported in severe patients 
with ARDS, there was a reduced CD8+ 
and CD4+ T cell counts in the peripheral 
blood with signs of hyperactivation, 
and an increase in CD4:CD8 ratio which 
may indicate migration of CD8+ T cells 
to the respiratory airway.32,33 There was 
also increased proinflammatory Th17 
phenotype in the CD4+ T cells pool, as 
opposed to IFNγ-producing Th1 cells that 
were identified in recovered patients.28,33
T cells reactive to nucleoprotein (N), 
main protease, and spike (S) could be 
detected in previously infected patients.28 
Interestingly, one study recently 
demonstrated that although with 
lower frequency, seronegative healthy 
individuals also contain a population 
of anti-spike (S) CD4+ T cells. Whilst 
these CD4+ T cells in COVID-19 patients 
recognized both RBD-containing S1 
subunit and S2 subunit of S protein, cells 
from the healthy controls only recognized 
S2 subunit but not S1, suggesting that 
RBD-S1 is the major epitope for inducing 
CD4+ T cell response.34
While T cell response are inarguably 
vital for successful viral clearance, T 
cell-dependent cytokine production and 
particularly CD8+ T cell-mediated direct 
cytotoxicity, can potentially cause tissue 
injury and exacerbate inflammation 
if not cautiously controlled. Viral 
dissemination and uncontrolled infection 
are key drivers for severe SARS-CoV-2 
infection. A dysregulation of innate 
responses undoubtedly plays a crucial 
role in the failure to control the virus at 
the early stage. However, it is likely that 
dysregulation in adaptive responses also 
contributes to immunopathology later 
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during infection. Uncontrolled CD8+ T 
cell responses may directly contribute to 
lung pathology in ARDS, as evidenced by 
the presence of T cells in the lung section 
and high concentration of cytotoxic 
granules in CD8+ T cells indicating high 
toxicity status of these cells.20,33
The prolonged subacute rather than 
acute clinical characteristics of COVID-19 
infection could potentially lead to T 
cell exhaustion and depletion, which 
manifest as progressive lymphopenia 
and immunosuppression in severe 
patients (FIGURE 5). Indeed, one study 
has demonstrated that both CD4+ and 
CD8+ T cells in COVID-19 patients highly 
expressed markers of T cell exhaustion, 
such as programmed cell death protein 
(PD)-1 and T-cell immunoglobulin 
mucin (Tim)-3.35 In contrast, peripheral 
T cells from recovering patients display 
signs of effective adaptive immune 
response, including clonal expansion, T 
cell activation, and memory formation. 
Therefore, it is currently proposed 
that during early infection with SARS-
CoV-2, as a result of rapid expansion, 
effector CD8+ T cells contribute to lung 
inflammation, and later in the process, 
persistent viral infection may cause T 
cell exhaustion and depletion, leading to 
more severe conditions and fatality.25
FIGURE 5. Immune responses in acute and uncontrolled viral infection [modified from 25]
CONCLUSION
COVID-19 is a serious respiratory 
disease   caused   by  a   novel 
betacoronavirus, SARS-CoV-2, which 
exhibits homologies with other 
coronaviruses causing previously 
pandemic SARS and MERS. Entry to the 
host cells depends on the interaction of 
viral spike protein with ACE2 receptor 
on the target cell surface. Disease 
transmission from infected to healthy 
individuals has been thought to occur 
via respiratory droplets (primarily), 
close contacts, aerosols, and possibly 
faecal-oral. While most infected 
individuals have mild disease and even 
asymptomatic, a proportion of patients 
can develop severe disease and death 
due to ARDS and multi organ failure. 
The pathogenesis of COVID-19 has 
been thought to result not only from 
the direct impact of viral infection on 
tissue destruction but also from the 
complex interplay of the virus with the 
host immune responses. While innate 
and adaptive immune responses are 
inarguably important for controlling 
viral dissemination, an immune-
induced pathology has been proposed 
as a consequence of the virus ability 
to modify the host responses through 
various mechanisms, resulting in the 
dysregulation of both the innate and 
adaptive responses and severe clinical 
manifestations in the susceptible infected 
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individuals. As currently available data 
on the pathogenesis of this novel virus 
infection are still limited, its complexity 
necessitates further studies both in the 
in vitro and in vivo settings to better 
elucidate this process.
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